The NHS should run a mile from the genome sequencing goldrush
By David King,
The Guardian
| 02. 07. 2019
Genomics England’s plans to move into paid-for genome sequencing of healthy people has done more than raise eyebrows in the scientific world. Last week a parade of the genomics great and good – who had clearly not been informed of the plans announced last week by Matt Hancock, the health secretary – wrote to the Times saying this would “create two-tier access to services, where people who can pay are able to access services that are denied to those who cannot”.
Others have pointed out that the plans will create extra pressure on GPs, who will have to deal with a flood of “worried well” patients coming to them with DNA test results.
The idea is that new “genomics volunteers” will pay for the sequencing and for its interpretation, while agreeing to donate the results in anonymous form to the Genomics England databank. The fact that the volunteers are being asked to pay for test results, delivered by a healthcare provider rather than a private genetic-testing company, must give them the impression that there are personal health benefits to...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...